Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer

Department of Functional Genomics, Proteomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca 400015, Romania

⁷

Department of Urology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca 400015, Romania

Authors to whom correspondence should be addressed.

Medicina 2019, 55(9), 564; https://doi.org/10.3390/medicina55090564

Received: 15 July 2019 / Revised: 29 August 2019 / Accepted: 30 August 2019 / Published: 3 September 2019

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

Background and Objectives: Over decades, prostate cancer (PCa) has become one of the leading causes of cancer mortality in men. Extensive evidence exists that microRNAs (miRNAs or miRs) are key players in PCa and a new class of non-invasive cancer biomarkers. Materials and Methods: We performed miRNA profiling in plasma and tissues of PCa patients and attempted the validation of candidate individual miRs as biomarkers. Results: The comparison of tissue and plasma profiling results revealed five commonly dysregulated miRs, namely, miR-130a-3p, miR-145-5p, miR-148a-3p, miR-150-5p, and miR-365a-3p, of which only three show concordant changes—miR-130a-3p and miR-150-5p were downregulated and miR-148a-3p was upregulated in both tissue and plasma samples, respectively. MiR-150-5p was validated as significantly downregulated in both plasma and tissue cancer samples, with a fold change of −2.697 (p < 0.001), and −1.693 (p = 0.035), respectively. ROC analysis showed an area under the curve (AUC) of 0.817 (95% CI: 0.680–0.995) for plasma samples and 0.809 (95% CI: 0.616–1.001) for tissue samples. Conclusions: We provide data indicating that miR-150-5p plasma variations in PCa patients are associated with concordant changes in prostate cancer tissues; however, given the heterogeneous nature of previous findings of miR-150-5p expression in PCa cells, additional future studies of a larger sample size are warranted in order to confirm the biomarker potential and role of miRNA-150-5p in PCa biology. View Full-Text

Keywords: prostate cancer; microRNA-150-5p; biomarkers; plasma

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
ZIP-Document (ZIP, 18 KiB)

Share and Cite

MDPI and ACS Style

Paunescu, I.A.; Bardan, R.; Marcu, A.; Nitusca, D.; Dema, A.; Negru, S.; Balacescu, O.; Balacescu, L.; Cumpanas, A.; Sirbu, I.O.; Petrut, B.; Seclaman, E.; Marian, C. Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer. Medicina 2019, 55, 564. https://doi.org/10.3390/medicina55090564

AMA Style

Paunescu IA, Bardan R, Marcu A, Nitusca D, Dema A, Negru S, Balacescu O, Balacescu L, Cumpanas A, Sirbu IO, Petrut B, Seclaman E, Marian C. Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer. Medicina. 2019; 55(9):564. https://doi.org/10.3390/medicina55090564

Chicago/Turabian Style

Paunescu, Ionut A., Razvan Bardan, Anca Marcu, Diana Nitusca, Alis Dema, Serban Negru, Ovidiu Balacescu, Loredana Balacescu, Alin Cumpanas, Ioan O. Sirbu, Bogdan Petrut, Edward Seclaman, and Catalin Marian. 2019. "Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer" Medicina 55, no. 9: 564. https://doi.org/10.3390/medicina55090564

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI